India, Aug. 17 -- Optimus Pharma, a subsidiary of Sekhmet Pharmaventures, has become the first company in India to receive permission from the Drugs Controller General of India (DCGI) to manufacture and market Tapinarof Cream 1% w/w and the tapinarof bulk drug.

Tapinarof Cream 1% w/w is a non-steroidal topical treatment for plaque psoriasis in adults. Psoriasis is a chronic, non-communicable skin condition that the World Health Organization estimates affects at least 100 million people worldwide.

Indian studies place prevalence in the country between 0.44 and 2.8 percent, with plaque psoriasis the most common presentation.

With both the bulk drug and the finished formulation produced in-house, Optimus maintains control across the end-t...